Quince Therapeutics, Inc.

Historical 13F Holders

Symbol
QNCX
CUSIP
22053A107
All holders as of
Q1 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 22053A107 since 12/18/2024, largest first.

Filer % of Class Filed
Group One Trading LLC 13G 10.7% 3/5/2026
Event 2/28/2026
Nantahala Capital Management, LLC 13G/A
7.5% 5/15/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
Sofinnova Partners SAS 13G/A
2.7% 4/30/2025
Event 3/31/2025
Genextra S.p.A. 13G/A
0% 10/30/2025
Event 7/7/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q1 45 14.2 M $1.43 M
2025 Q4 69 20.1 M $67.5 M
2025 Q3 48 12.3 M $20.0 M
2025 Q2 44 7.75 M $12.8 M
2025 Q1 39 5.23 M $6.96 M
2024 Q4 40 5.11 M $9.55 M
2024 Q3 36 5.19 M $4.04 M
2024 Q2 49 6.26 M $4.69 M
2024 Q1 52 7.29 M $7.73 M
2023 Q4 48 7.46 M $7.84 M
2023 Q3 44 7.50 M $8.40 M
2023 Q2 45 8.98 M $13.5 M
2023 Q1 51 7.68 M $12.0 M
2022 Q4 57 5.46 M $3.48 M
2022 Q3 69 9.32 M $12.4 M
2022 Q2 80 11.7 M $26.0 M
2022 Q1 104 16.9 M $99.5 M
2021 Q4 133 19.7 M $249 M
2021 Q3 165 19.2 M $1.76 B
2021 Q2 121 18.5 M $983 M
2021 Q1 102 18.7 M $674 M
2020 Q4 100 17.7 M $491 M
2020 Q3 94 16.5 M $827 M
2020 Q2 85 15.5 M $715 M
2020 Q1 69 11.5 M $523 M
2019 Q4 54 10.7 M $600 M
2019 Q3 43 5.85 M $145 M
2019 Q2 39 2.46 M $104 M